Yale Cancer Center study validates combination therapy for aggressive endometrial cancer

June 29, 2020

Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research.

"The randomized, multi-institutional phase 2 trial studied 58 women with uterine serous carcinoma (USC) whose tumors expressed high levels of the HER2 protein, which is known to drive several forms of cancer in women," said Alessandro Santin, M.D., professor of gynecology, obstetrics & reproductive sciences, Leader of the Disease Aligned Research Team of the Gynecologic Oncology Program at Smilow Cancer Hospital and YCC, and senior author of the study. After surgery, women were either given a standard chemotherapy regimen of carboplatin and paclitaxel, or the same combination chemotherapy regimen followed by trastuzumab. Trastuzumab targets HER2, a surface receptor, and has long improved outcomes for women whose breast cancers display high levels of HER2 expression.

The combination therapy with trastuzumab was particularly effective among 41 women with advanced stage 3 and stage 4 USC receiving their first treatment for the disease. Average progression-free survival (PFS) doubled from about 9 months in the control arm to 18 months in women given the treatment, "which is unprecedented for this cancer," Santin said.

"Importantly, the trial showed no difference in toxicity between the two groups," said Santin. "Trastuzumab is a humanized antibody, a natural product of our bodies, and it is extremely well tolerated."

Each year, more than 65,650 women in the United States are diagnosed with endometrial cancer, and over 12,590 die of the disease. "As this country's population ages and obesity rates climb, these numbers are likely to double in the next decade," said Santin. "USC accounts for only three to ten percent of all these cases of endometrial cancer, but it kills over 40% of the patients because it's so aggressive," he added.

Among the 17 women in the study where USC recurred, the combination treatment prolonged the disease-free interval but did not significantly improve survival when compared to the standard chemotherapy regimen. "These are patients who return with large amounts of metastatic cancer," Santin said. "Most likely their tumor burden is so high and heterogenous that the tumor becomes resistant also to trastuzumab."

In 2018, after examining preliminary data on the phase 2 trial, the National Comprehensive Cancer Network (NCCN) adopted the chemotherapy/trastuzumab combination for new treatment of women with HER2-positive USC as a guideline for treatment. NCCN is widely recognized by both clinicians and payers as the U.S. standard-setting body for oncology clinical guidelines. "With those NCCN guidelines, everybody started using it," Santin said. Now that the final results for the trial are published, he expects much broader worldwide adoption of the combination.
Amanda Fader, M.D., was first author on the paper. Yale's Natalia Buza, M.D., Pei Hui, M.D., Ph.D., Osama Abdelghany, Stefania Bellone, Ph.D., Masoud Azodi, M.D., Elena Ratner, M.D., Dan-Arin Silasi, M.D., and Peter Schwartz, M.D., contributed to the study.

Roche's Genentech subsidiary provided funding for the research.

Yale University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.